Loading...
•
Sep 30, 2022
Relmada Q3 2022 Earnings Report
Relmada reported preliminary and unaudited financial results for Q3 2022 and provided a corporate update.
Key Takeaways
Relmada Therapeutics announced Q3 2022 financial results, with a focus on the ongoing evaluation of REL-1017 for major depressive disorder (MDD). Top-line results from the RELIANCE III trial were recently announced, and the company anticipates further results from RELIANCE I before the year's end. Enrollment continues for RELIANCE II, with top-line results expected in 2023.
RELIANCE III top-line results are being further evaluated.
Top-line results from RELIANCE I are expected before the end of the year.
Enrollment continues in RELIANCE II, with top-line results anticipated in 2023.
Relmada remains confident in REL-1017's potential for adjunctive treatment of MDD.
Forward Guidance
Relmada is focused on advancing REL-1017 in clinical development and expects top-line results from RELIANCE I before the end of the year and RELIANCE II in 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...